Cancer Treatment Is a Team Sport — Oncology Done Right

Cancer care generates more data per patient than almost any other specialty. Imaging studies from CT, MRI, and PET scans. Pathology reports with molecular markers, receptor status, and staging details. Lab work before, during, and after every treatment cycle. Chemotherapy orders with weight-based or BSA-based dosing that changes as the patient's condition evolves. Radiation plans. Surgical notes. Genetic test results. Clinical trial eligibility data. And all of this needs to be available to multiple providers across multiple departments, often across multiple facilities.

The problems with fragmented oncology data aren't theoretical — they're daily realities:

• Protocol deviations from memory — When a chemotherapy protocol isn't templated in the system, providers reconstruct it from memory or from a printed reference. A missed pre-medication, a dose that should have been adjusted for renal function, a cycle interval that drifts because nobody's tracking the calendar — these deviations accumulate silently.
• Dose calculation errors — Chemotherapy dosing based on body surface area (BSA) requires accurate, current height and weight measurements. When the last recorded weight is from two months and fifteen pounds ago, the calculated dose is wrong. Not a little wrong. Potentially dangerously wrong.
• Toxicity data lost in progress notes — A patient reports Grade 2 nausea during cycle three. The nurse documents it in a free-text progress note. By cycle four, the oncologist doesn't see it because it's buried in narrative text, not structured data. The same regimen continues without the dose reduction that the toxicity warranted.
• Tumor board preparation takes hours — Preparing a case for tumor board means gathering imaging from the PACS, pathology from the lab system, treatment history from the EMR, and genomic results from a third-party portal. Someone — usually a fellow or a coordinator — spends hours assembling this into a presentation. Then during the conference, half the attendees can't see the imaging clearly because it's displayed on a projector from a laptop screen.

Cancer doesn't wait for your systems to sync. Neither should your oncology team.

Chemotherapy is not a single drug given once. It's a regimen — multiple agents, given in a specific sequence, at specific intervals, with specific pre-medications and supportive care, adjusted for the patient's body surface area, organ function, and response to prior cycles. Getting any part of this wrong isn't a clerical error. It's a patient safety event.

GoEMR's oncology module starts with the protocol library — a structured, evidence-based collection of chemotherapy regimens that removes the need for manual reconstruction:

• Pre-built regimen templates — Standard-of-care protocols for the most common cancer types are available as structured templates. FOLFOX for colorectal cancer. AC-T for breast cancer. R-CHOP for lymphoma. Cisplatin-etoposide for small cell lung cancer. Each template includes the agents, doses, schedule, pre-medications, hydration protocols, and antiemetic regimens defined by NCCN guidelines. The oncologist selects the protocol and the system builds the order set — no re-entry, no reconstruction from memory.
• BSA-calculated dosing — When a protocol is applied to a patient, GoEMR automatically calculates the dose for each agent based on the patient's most recent height and weight. If the patient's weight has changed since the last cycle, the system prompts for a new measurement before allowing the order to proceed. The dose calculation is transparent — the provider sees the BSA, the formula, and the resulting dose, and can adjust if clinically indicated.
• Dose modification rules — Real-world oncology requires constant dose adjustments. Renal function declines, requiring a carboplatin dose reduction based on the Calvert formula. A patient develops peripheral neuropathy, requiring an oxaliplatin dose cap. Hepatic impairment changes the metabolism of a taxane. GoEMR's protocol templates include built-in dose modification rules that flag when an adjustment is warranted based on lab values and toxicity grades.
• Custom protocol support — Not every patient fits a standard regimen. Clinical trials, off-label combinations, and individualized dosing are part of oncology practice. GoEMR allows oncologists to create custom protocols, define dose parameters, and save them as templates for future use. Custom protocols get the same safety checks as standard ones — interaction screening, allergy verification, and dose-limit alerts.
• Order verification workflow — Every chemotherapy order goes through a multi-step verification before reaching the infusion suite. The oncologist signs the order. The pharmacist reviews the dose calculations, checks for interactions, and verifies the preparation instructions. The infusion nurse confirms patient identity, reviews the protocol, and verifies the rate and duration before administration. Each step is documented in GoEMR with timestamps and digital signatures.

A chemotherapy order that relies on memory, mental math, and manual transcription is an accident that hasn't happened yet. GoEMR's protocol templates ensure that every order starts from evidence, calculates from current data, and passes through verification before it reaches the patient.

Chemotherapy works by killing rapidly dividing cells. The problem is that it doesn't distinguish perfectly between cancer cells and healthy ones. The result is toxicity — nausea, fatigue, neuropathy, bone marrow suppression, mucositis, hepatotoxicity, nephrotoxicity — a spectrum of side effects that range from uncomfortable to life-threatening. Managing these toxicities is as much a part of oncology as prescribing the chemotherapy itself.

The Common Terminology Criteria for Adverse Events (CTCAE) provides a standardized grading system for toxicities, from Grade 1 (mild) to Grade 5 (death). GoEMR builds CTCAE grading directly into the treatment workflow:

• Structured toxicity assessment — Before each cycle, GoEMR presents a toxicity assessment form specific to the regimen being administered. For a platinum-based regimen, the form includes fields for nausea/vomiting grade, neuropathy grade, audiometry findings, renal function, and blood counts. The provider selects the CTCAE grade for each toxicity — the data is structured, not buried in a free-text note.
• Automatic dose-hold and modification triggers — When a toxicity grade exceeds a protocol-defined threshold, GoEMR flags the order. A Grade 3 neutropenia triggers a treatment hold recommendation. A Grade 2 neuropathy on an oxaliplatin regimen triggers a dose reduction recommendation. The provider can accept, modify, or override the recommendation — but they can't miss it, because the system won't let the order proceed without acknowledgment.
• Cycle timeline visualization — GoEMR displays a visual timeline of every treatment cycle: the date administered, the agents given, the doses delivered, the toxicities reported, and the lab values at each point. This longitudinal view makes trends immediately visible. If neutrophil counts have been dropping progressively across three cycles, the trend is obvious on the timeline even if each individual value was within acceptable limits.
• Treatment delay tracking — When a cycle is delayed due to toxicity or scheduling, GoEMR tracks the actual interval versus the planned interval. Cumulative delays are calculated automatically. If a patient's treatment has been delayed by a total of three weeks across six cycles, the oncologist sees that context when planning the next cycle — and can factor it into response assessment and restaging decisions.
• Patient-reported outcomes integration — Between clinic visits, patients can report symptoms through GoEMR's patient portal. A patient who develops a fever at home on day 10 of a cycle can report it immediately. The care team receives an alert, triages the report, and can intervene before the patient becomes septic. This closes the gap between the patient's lived experience and the oncologist's next scheduled assessment.

A toxicity that isn't graded is a toxicity that won't be managed. Structured data turns side effects into actionable clinical decisions.

Tumor board is where the most important decisions in cancer care get made. It's where the surgeon, the medical oncologist, the radiation oncologist, the pathologist, and the radiologist sit in the same room — or increasingly, the same virtual conference — and review a patient's case together. The treatment plan that emerges from tumor board reflects the combined expertise of every specialty involved. When tumor board works well, it's the gold standard of multidisciplinary care.

When it doesn't work well, it's a logistical nightmare. GoEMR's integrated tumor board module addresses every friction point:

• One-click case preparation — Instead of manually assembling imaging, pathology, labs, and treatment history into a slide deck, the presenting physician selects the patient and GoEMR generates a case summary with all relevant data pre-loaded. CT images, pathology slides with annotations, lab trends, treatment timeline, and genomic results are all accessible from the case view — no USB drives, no switching between systems, no "let me pull that up."
• Integrated diagnostic imaging — DICOM-compatible imaging from CT, MRI, PET, and ultrasound is viewable directly within the tumor board interface. Attendees can zoom, scroll through slices, and adjust windowing without leaving the conference view. The radiologist can mark findings in real time, and those annotations persist in the patient's record for future reference.
• Pathology slide integration — Digital pathology slides, when available, are displayed alongside the clinical data. The pathologist can highlight regions of interest, annotate margins, and reference molecular markers — all visible to every attendee simultaneously. For institutions still using glass slides, high-resolution photographs uploaded to GoEMR serve the same presentation purpose.
• Virtual attendance and recording — For multi-site cancer programs, GoEMR supports virtual tumor board attendance with video conferencing integrated into the case view. Remote participants see the same clinical data as in-person attendees. Sessions can be recorded for providers who couldn't attend, with timestamps linked to specific cases for easy review.
• Decision documentation — The treatment recommendation that emerges from tumor board is documented directly in the patient's chart. The recommended plan, the rationale, the participating providers, and any dissenting opinions are captured in a structured note. This recommendation then serves as the basis for the treatment order — closing the loop between discussion and action.

Tumor board should be where the best minds come together to make the best decision for the patient. It shouldn't be where half the meeting is spent troubleshooting a projector and the other half is spent waiting for someone to find the PET scan.

Cancer treatment doesn't end when the last cycle of chemotherapy is administered or the final radiation session is delivered. What follows is survivorship — a phase of care that requires its own monitoring, its own screening schedules, and its own documentation. Survivors face long-term risks from the treatments that saved them: cardiotoxicity from anthracyclines, secondary malignancies from radiation, neuropathy from platinum agents, endocrine effects from hormonal therapies. These risks need to be tracked for years, sometimes for life.

The Institute of Medicine recommended in 2006 that every cancer patient receive a survivorship care plan at the completion of treatment. Nearly two decades later, most practices still don't generate them consistently. GoEMR changes that:

• Auto-generated treatment summaries — GoEMR compiles the patient's complete treatment history into a structured summary: diagnosis, staging, surgery dates and findings, chemotherapy regimens with cumulative doses, radiation fields and total dose, and any treatment modifications. This summary is generated automatically from the data already in the system — no manual assembly required.
• Risk-stratified surveillance schedules — Based on the cancer type, stage, and treatments received, GoEMR generates a surveillance schedule aligned with NCCN survivorship guidelines. A breast cancer survivor who received anthracycline-based chemotherapy gets cardiac monitoring recommendations. A colorectal cancer survivor gets a colonoscopy schedule. A Hodgkin lymphoma survivor who received mediastinal radiation gets breast cancer screening recommendations. The schedule is specific to the patient, not generic.
• Primary care handoff documentation — When a survivor transitions from oncology follow-up to primary care, GoEMR generates a handoff document that tells the primary care provider exactly what to watch for, when to screen, and what symptoms should trigger a referral back to oncology. This document bridges the gap between specialty and primary care — a gap where late recurrences and treatment-related complications often go undetected.
• Patient-facing survivorship plan — GoEMR also generates a patient-friendly version of the survivorship plan: what treatments they received, what follow-up they need, what symptoms to watch for, and who to contact with concerns. Patients who understand their survivorship plan are more likely to adhere to surveillance schedules — and more likely to catch problems early.

Beating cancer is only half the battle. Survivorship care is how you make sure the victory lasts.

Cancer care demands more coordination than any other area of medicine. Multiple specialists, multiple treatment modalities, multiple cycles of therapy, and a disease that evolves throughout treatment — all of it generating data that every member of the care team needs to see, in real time, in context.

GoEMR's Oncology module was built for this complexity:

• Regimen libraries — Evidence-based protocol templates with BSA-calculated dosing, pre-medications, and supportive care built in. Select the regimen, verify the dose, sign the order.
• CTCAE grading — Structured toxicity assessment at every cycle, with automatic dose modification triggers that prevent toxicity from being overlooked.
• Cycle tracking — Visual timelines showing every cycle, every dose, every delay, and every toxicity — the complete treatment story at a glance.
• Tumor board integration — One-click case preparation, embedded imaging and pathology, virtual attendance, and decision documentation that flows directly into the treatment plan.
• Survivorship care plans — Auto-generated treatment summaries and risk-stratified surveillance schedules that follow the patient from active treatment through long-term survivorship.

Every cancer patient deserves a care team that's working from the same playbook, seeing the same data, and making decisions together. GoEMR doesn't just store oncology data — it connects it, so the team can focus on what matters: the patient in front of them.